Method and composition for treating hepatitis B

• US 5,650,167 A
• Filed: 11/16/1995
• Issued: 07/22/1997
• Est. Priority Date: 11/16/1995
• Status: Expired due to Fees

• Current Assignee: DAWA Incorporated
• Original Assignee: DAWA Incorporated
• Inventors: Allison, Anthony C.
• Primary Examiner(s): Bawa, Raj
• Application Number:
  US08/559,548
• Time in Patent Office: 614 Days
• Field of Search: 424/422, 424/451, 424/464, 514/894, 514/510, 514/577
• US Class Current: 424/451
• CPC Class Codes: A61K 31/192 having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid cannabinoids A61K31/658
• CPC Class Codes: A61K 31/216 of acids having aromatic rings, e.g. benactizyne, clofibrate
• CPC Class Codes: A61K 47/26 Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
• CPC Class Codes: A61K 9/0095 Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches A61K9/0007 takes precedence; eatable gels or foams A61K9/0056; oral mucosa adhesive forms A61K9/006
• CPC Class Codes: A61K 9/2018 Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
• CPC Class Codes: A61K 9/4858 Organic compounds

Abstract

Disclosed is a method of inhibiting hepatitis B infection by administering a therapeutically effective amount of a compound having the formula (Formula 1): ##STR1## wherein R1 is selected from the group consisting of H, lower alkanoyl, lower arylalkylacyl, arylacyl, and C-1-linked saccharide, and R2 is separately selected from the group consisting of H, lower alkyl, lower arylalkyl, aryl, and C-1-linked saccharide. The compounds may also be used to treat other conditions, such as inflammatory bowel disease, autoimmune diseases, transplant rejection, septic shock, and for protection against irradiation damage. Novel celastrol derivatives are also disclosed.

Claims

1. A method of inhibiting hepatitis B infection in a mammalian subject, comprising administering to the subject a therapeutically effective amount of a compound having the formula:

##STR3## wherein R1 is selected from the group consisting of H and lower alkanoyl, and R2 is separately selected from the group consisting of H and lower alkyl.

2. The method of claim 1, wherein R1 and R2 are H.

3. The method of claim 1, wherein R1 is acetyl, and R2 is ethyl.

4. The method of claim 1, wherein R1 is H and R2 is ethyl.

5. The method of claim 1, wherein R1 is acetyl and R2 is H.

6. The method of claim 1, wherein the compound is administered orally.